Advanced

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

Lindholm, Åsa; Bixo, Marie; Bjorn, Inger; Wölner-Hanssen, Pål LU ; Eliasson, Mats; Larsson, Anders; Johnson, Owe and Sundström Poromaa, Inger Sundström (2008) In Fertility and Sterility 89(5). p.1221-1228
Abstract
Objective: To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS). Design: Investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial. Setting: Departments of Obstetrics and Gynecology in primary care, referral centers, and private practice. Patient(s): Forty-two patients with confirmed PCOS were included in the study, and 34 patients completed the study. Intervention: Sibutramine 15 mg once daily together with brief lifestyle modification was compare with placebo together with brief lifestyle modification. Main Outcome Measure(s): The primary endpoint was to assess weight loss. Secondary endpoints included... (More)
Objective: To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS). Design: Investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial. Setting: Departments of Obstetrics and Gynecology in primary care, referral centers, and private practice. Patient(s): Forty-two patients with confirmed PCOS were included in the study, and 34 patients completed the study. Intervention: Sibutramine 15 mg once daily together with brief lifestyle modification was compare with placebo together with brief lifestyle modification. Main Outcome Measure(s): The primary endpoint was to assess weight loss. Secondary endpoints included the efficacy of sibutramine for treatment of menstrual pattern and cardiovascular risk factors. Result(s): After 6 months the sibutramine group had lost 7.8 +/- 5.1 kg compared with a weight loss of 2.8 +/- 6.2 kg in the placebo group. Sibutramine treatment resulted in significant decreases in apolipoprotein B, apolipoprotein B/apolipoprotein A ratio, triglycerides, and cystatin C levels. Conclusion(s): Sibutramine in combination with lifestyle intervention results in significant weight reduction in obese patients with PCOS. In addition to the weight loss, sibutramine seems to have beneficial effects on metabolic and cardiovascular risk factors. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
randomized clinical trial, polycystic ovary syndrome, sibutramine, obesity
in
Fertility and Sterility
volume
89
issue
5
pages
1221 - 1228
publisher
Elsevier
external identifiers
  • wos:000256075700027
  • scopus:43449104710
ISSN
1556-5653
DOI
10.1016/j.fertnstert.2007.05.002
language
English
LU publication?
yes
id
4c50be2c-3c30-4b07-86c0-62fae8320c40 (old id 1203410)
date added to LUP
2008-09-16 16:02:43
date last changed
2017-04-30 07:42:44
@article{4c50be2c-3c30-4b07-86c0-62fae8320c40,
  abstract     = {Objective: To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS). Design: Investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial. Setting: Departments of Obstetrics and Gynecology in primary care, referral centers, and private practice. Patient(s): Forty-two patients with confirmed PCOS were included in the study, and 34 patients completed the study. Intervention: Sibutramine 15 mg once daily together with brief lifestyle modification was compare with placebo together with brief lifestyle modification. Main Outcome Measure(s): The primary endpoint was to assess weight loss. Secondary endpoints included the efficacy of sibutramine for treatment of menstrual pattern and cardiovascular risk factors. Result(s): After 6 months the sibutramine group had lost 7.8 +/- 5.1 kg compared with a weight loss of 2.8 +/- 6.2 kg in the placebo group. Sibutramine treatment resulted in significant decreases in apolipoprotein B, apolipoprotein B/apolipoprotein A ratio, triglycerides, and cystatin C levels. Conclusion(s): Sibutramine in combination with lifestyle intervention results in significant weight reduction in obese patients with PCOS. In addition to the weight loss, sibutramine seems to have beneficial effects on metabolic and cardiovascular risk factors.},
  author       = {Lindholm, Åsa and Bixo, Marie and Bjorn, Inger and Wölner-Hanssen, Pål and Eliasson, Mats and Larsson, Anders and Johnson, Owe and Sundström Poromaa, Inger Sundström},
  issn         = {1556-5653},
  keyword      = {randomized clinical trial,polycystic ovary syndrome,sibutramine,obesity},
  language     = {eng},
  number       = {5},
  pages        = {1221--1228},
  publisher    = {Elsevier},
  series       = {Fertility and Sterility},
  title        = {Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial},
  url          = {http://dx.doi.org/10.1016/j.fertnstert.2007.05.002},
  volume       = {89},
  year         = {2008},
}